Redeye comments on Kancera reporting positive top-line results in its phase Ib/IIa KANDOVA study with KAND567 in ovarian cancer.
Redeye comments on this morning’s news that Kancera has received positive feedback on the planned clinical program for KAND567 in ST-elevati...
Redeye returns following Kancera's Q1 report. The investment case is currently centred around the letter of intent with Recardio Inc.
Redeye provides a brief comment on Kancera’s update regarding the collaboration with Recardio and the clinical program.
Redeye comments on Kancera’s announcement of a letter of intent with Recardio Inc.
Redeye returns following Kancera's Q4 report. We note that 2025 is shaping up to be a pivotal year, laying the foundation for the planned st...
Redeye returns following Kancera’s strategic shift to focus on cardiovascular diseases and its Q3 report.
Redeye comments on yesterday’s news that Kancera will concentrate its resources on cardiovascular diseases.
Redeye provides a research update following the Q2 2024 report from Kancera.
Redeye provides an initial comment on the Q2 2024 report from Kancera, which showed lower operating costs than we had foreseen.
Redeye leaves a short comment following Kancera's announcement from earlier this morning regarding clinical advancements in the KANDOVA stud...
Redeye initiates coverage of Kancera, a Swedish life science company developing candidates targeting myocardial infarction and ovarian cance...
